Gary E. Gibson
From Wikipedia, the free encyclopedia
Weill Cornell Medicine
Gary E. Gibson | |
|---|---|
| Scientific career | |
| Fields | Neuroscience, mitochondrial biology, neurodegeneration |
| Institutions | UCLA Weill Cornell Medicine |
Gary E. Gibson is an American neuroscientist specializing in mitochondrial biology and metabolic dysfunction related to neurodegeneration. He serves as the Lab Director of the Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration at the Burke Neurological Institute and holds the position of Professor of Neuroscience with tenure at the Brain and Mind Research Institute of Weill Cornell Medicine. He also served as associate director of the Dementia Research Service.[1][2]
Gibson earned his Bachelor of Science degree in Zoology and Chemistry from the University of Wyoming. He subsequently pursued a Ph.D. in Physiology with a focus on Biochemistry and Neuroscience at Cornell University. After completing his doctoral studies, he conducted postdoctoral research at the University of California, Los Angeles (UCLA). Following his postdoctoral work, he joined the faculty at UCLA before moving to Weill Cornell Medicine and the Burke Neurological Institute.[1][2][3]
Career
Gibson has made significant contributions to the understanding of mitochondrial function and metabolic dysfunction in age-related neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's diseases as well as stroke. His research investigates how abnormalities in the brain's use of oxygen and glucose lead to neurodegenerative diseases, with a focus on identifying therapeutic interventions.[4][5]
Gibson and his team employ cellular (including stem cells and human fibroblasts) and animal models, as well as samples from human patients and isolated proteins to study the role of thiamine (vitamin B1), glucose, oxygen metabolism and mitochondria in brain function and to test potential drug therapies. His research revealed that post-translational modification of proteins by glucose metabolites lead to a broad range of functional/pathological changes.[6][7]
Throughout his career, Gibson has been continuously funded by the National Institutes of Health (NIH) and has served on over 20 NIH review panels. He reviews grants for organizations such as the Alzheimer's Association, Alzheimer's Drug Discovery Foundation, and the American Federation for Aging Research.[8][9][10]
Awards and honors
Gibson was recognized with the American Society for Neurochemistry's Outstanding Young Investigator Award and has delivered lectures at many institutions. Notable presentations include the Dean's Hour at Cornell University Medical College, the NIH Director's Talk, and the Visek Lectureship at the University of Illinois.[1][2]
Professional affiliations and editorial work
Gibson is a member of the American Society for Neurochemistry (where he served as secretary in 2005–2006), the Society for Neuroscience, the International Society for Neurochemistry, the International Society for Cerebral Blood Flow and Metabolism, and the American Society for Nutrition. He holds three U.S. patents related to his research and has served on the editorial boards of numerous scientific journals, including Neurochemical Research, Neurochemical International (as Associate Editor), Journal of Neurochemistry, and Journal of Alzheimer's Disease.[1][2][11]